1. Introduction {#sec1-cancers-10-00283}
===============

Cholangiocarcinoma (CCA) is a cancer of bile duct epithelia thought to arise as a result of chronic inflammation of the liver and bile ducts. The incidence of CCA has increased gradually worldwide during the last three decades \[[@B1-cancers-10-00283],[@B2-cancers-10-00283],[@B3-cancers-10-00283],[@B4-cancers-10-00283]\]. The incidence of this disease is highest in Southeast Asia \[[@B5-cancers-10-00283]\] particularly in the northeastern provinces of Thailand due to persistent liver fluke infection \[[@B6-cancers-10-00283],[@B7-cancers-10-00283]\]. Although, surgery is considered the best treatment option, most patients are not suitable for surgery on presentation \[[@B8-cancers-10-00283],[@B9-cancers-10-00283]\]. Moreover, approximately 70% of intrahepatic cholangiocarcinoma patients have a recurrence of disease post-surgery \[[@B10-cancers-10-00283]\]. Adjuvant capecitabine treatment is effective post-surgery but median survival is only around four years \[[@B11-cancers-10-00283]\]. Non-resectable disease can be treated using radiation and gemcitabine and cisplatin as first-line chemotherapy. However, median overall survival remains very poor at only around 12 months \[[@B12-cancers-10-00283]\]. Therefore, there is an urgent unmet clinical need for new adjuvant therapies that could prevent recurrence as well as for new and effective second line drug treatments.

Protein kinase CK2 (previously casein kinase II), a ubiquitously expressed serine/threonine kinase, forms a tetrameric holoenzyme composed of two catalytic subunits, which are alpha (α) or alpha′ (α′), or a combination of both, and two regulatory beta (β) subunits \[[@B13-cancers-10-00283]\]. CK2 levels in many cancer types are abnormally high \[[@B14-cancers-10-00283]\]. CK2 promotes cell survival and was shown to suppress apoptosis in various cancer types, such as HeLa and the gastric cancer cell line SGC-7901, where CK2 phosphorylated apoptosis repressor with caspase recruitment domain (ARC) \[[@B15-cancers-10-00283]\]. In addition, CK2 promoted malignant peripheral nerve sheath tumors (MPNST) cell survival by stabilizing β-catenin \[[@B16-cancers-10-00283]\]. Downregulation of CK2 with short hairpin RNA (shRNA) or with CX-4945 also known as Silmitasertib, a CK2 inhibitor, caused MPNST cells to arrest in the G2/M phase and undergo apoptosis \[[@B16-cancers-10-00283]\]. Downregulation of CK2 with small interfering (siRNA) or by using CX-4945 induced apoptosis in non-small cell lung cancer cell lines by downregulation of Akt and its downstream signals \[[@B17-cancers-10-00283]\]. Similarly, apoptosis was observed in acute myeloid leukemia cells by a p53-dependent mechanism after CK2 knockdown or CX-4945 application \[[@B18-cancers-10-00283]\]. Furthermore, stable knockdown of CK2 sensitized HEp-2 laryngeal carcinoma cells to cisplatin-induced apoptosis \[[@B19-cancers-10-00283]\].

CK2 has been proposed as a drug target for many cancers. Downregulation of protein kinase CK2 induced the senescent phenotype in human diploid fibroblast IMR-90 cells \[[@B20-cancers-10-00283]\], and decreased androgen receptor nuclear translocation, which led to a reduced expression of genes required for prostate cancer cell proliferation \[[@B21-cancers-10-00283]\]. CX-4945 has also been shown to decrease the survival of many cancer cell types including bladder \[[@B22-cancers-10-00283]\], hematological \[[@B23-cancers-10-00283],[@B24-cancers-10-00283]\], prostate \[[@B25-cancers-10-00283]\], and breast cancer cells \[[@B26-cancers-10-00283]\]. CX-4945 up to 10 µM showed an inhibition on Akt phosphorylation in prostate cancer, PC3 cells, and \[[@B27-cancers-10-00283]\] non-small cell lung cancer cells, H1299, Calu-1, and H358 \[[@B17-cancers-10-00283]\]. It also induced cell cycle arrest and apoptosis in the aforementioned prostate and non-small cell lung cancer cell lines \[[@B17-cancers-10-00283],[@B27-cancers-10-00283]\]. An in vivo study showed that CX-4045 up to 75 mg/kg was safe in mice and inhibited PC3 tumor xenograft growth \[[@B27-cancers-10-00283]\]. In primary human mucin- and mixed-intrahepatic CCA, CX-4945 up to 50 µM significantly decreased the viability of primary human cell cultures and induced apoptosis at 10 µM, whereas Cytokeratin 19 (CK19)-positive cells required a higher dose at 30 µM \[[@B28-cancers-10-00283]\]. CX-4945 increased the number of γ-H2AX positive cells that are a marker for DNA double-strand breaks \[[@B28-cancers-10-00283]\]. However, inhibition of DNA-PK (DNA-dependent protein kinase), previously reported as downstream of CK2 in glioblastoma cells \[[@B29-cancers-10-00283]\], unexpectedly reduced γ-H2AX positive cells in primary human intrahepatic CCA cells \[[@B28-cancers-10-00283]\]. This suggested that DNA-PK and also possibly CK2 in the setting of CCA acted as negative modulators of DNA double strand break repair, which is opposite from the mechanism reported in glioblastoma \[[@B29-cancers-10-00283]\] and leukemia \[[@B30-cancers-10-00283]\].

Interestingly, CX-4945 at 1 and 10 µM was recently shown to have off-target effects. The inhibition of Cdc2-like kinases (Clks) from these doses of CX-4945 resulted in a suppression of phosphorylation of serine/arginine (S/R) rich proteins in mammalian cells \[[@B31-cancers-10-00283]\]. In addition, CX-4945 has been shown to affect alternative splicing of a wide range of genes, including CK2 itself, in a CK2-independent manner in the HEK293T cell line \[[@B31-cancers-10-00283]\].

Although apoptosis is the most widely recognized form of physiological programmed cell death, several non-apoptotic cell death mechanisms have been reported to date. One distinct characteristic of many non-apoptotic cell death mechanisms is the formation of cytoplasmic vacuoles. The origin of the cytoplasmic vacuoles in different non-canonical cell death mechanisms is different yet not unique. One relatively well known non-apoptotic cell death is autophagy. Autophagy forms autophagosomes that are double-membrane vacuoles \[[@B32-cancers-10-00283],[@B33-cancers-10-00283],[@B34-cancers-10-00283]\]. In contrast, methuosis, a recently described cell death mechanism, utilizes single-membrane vacuoles from macropinocytosis \[[@B35-cancers-10-00283],[@B36-cancers-10-00283],[@B37-cancers-10-00283]\]. A few other types of non-apoptotic cell death mechanisms share a similar origin for the formation of cytoplasmic vacuoles. Oncosis, paraptosis, and necroptosis form vacuoles from endoplasmic reticulum (ER) and mitochondria \[[@B35-cancers-10-00283],[@B38-cancers-10-00283],[@B39-cancers-10-00283],[@B40-cancers-10-00283],[@B41-cancers-10-00283],[@B42-cancers-10-00283]\].

Methuosis is derived from the Greek methuo (to drink to intoxication) because the hallmark of this form of cell death is the formation of large fluid-filled vacuoles derived from macropinosomes. The demise of the cell resembles many forms of necrosis, with loss of metabolic capacity and plasma membrane integrity. Moreover, cell shrinkage and nuclear fragmentation associated with apoptosis are not observed \[[@B35-cancers-10-00283]\]. Methuosis was initially defined in glioblastoma cells after ectopic expression of activated Ras \[[@B36-cancers-10-00283],[@B37-cancers-10-00283]\], but recent reports have described small molecules, including indole-based chalcone 3-(2-methyl-1H indol-3-yl)-1-(4-pyridinyl)-2-propen-1-one (MIPP) and MOMIPP, which has a 5-methoxy group added to the indole ring of MIPP, that can induce the features of methuosis \[[@B37-cancers-10-00283],[@B43-cancers-10-00283]\].

Herein, we report for the first time that CX-4945 at low doses stimulated CCA cell invasion due to an upregulation of matrix metallopeptidase 7 (MMP-7) and matrix metallopeptidase 9 (MMP-9). Also, CX-4945 induced cytosolic vacuolization, which met the criteria of methuosis, via a CK2-independent mechanism in a dose- and time-dependent manner.

2. Results {#sec2-cancers-10-00283}
==========

2.1. CX-4945 Inhibits CK2 Activity at High Dose {#sec2dot1-cancers-10-00283}
-----------------------------------------------

To investigate the effects of CX-4945 on CCA cells, we treated three CCA cell lines with increasing amounts of this drug. CX-4945 reduced CK2 activity in a dose-dependent manner 4 h post-treatment as determined using Western blotting with an antibody that recognizes phosphorylated CK2 sites in multiple proteins ([Figure 1](#cancers-10-00283-f001){ref-type="fig"}a). The CCA cell lines all showed a reduction in multiple phospho-CK2 substrates with apparent molecular masses of approximately 200, 180, 100, 60, 37, 35, and 33 kDa as indicated by arrows in the Figure ([Figure 1](#cancers-10-00283-f001){ref-type="fig"}a).

2.2. CX-4945 Treatment Inhibits CCA Cell Proliferation {#sec2dot2-cancers-10-00283}
------------------------------------------------------

To determine the effects of CX-4945 on CCA cell proliferation we treated the three cell lines described above and examined the effect on cell number and 5-bromo-2′-deoxyuridine (BrdU) incorporation. After 5 days of treatment, CX-4945 at 5 µM or higher doses reduced CCA cell number in all of the cell lines ([Figure 1](#cancers-10-00283-f001){ref-type="fig"}b). CX-4945 at 5 µM reduced CCA cell number to approximately 50% of the vehicle control in HuCCA-1, KKU-M213 cells and in CCLP-1 approximately to 70% as compared to vehicle control group at 5-days post-treatment. CCA cells treated with 10 and 15 µM CX-4945 did not increase in number over 5 days in culture ([Figure 1](#cancers-10-00283-f001){ref-type="fig"}b), and higher doses of CX-4945 (25 and 50 µM) decreased cell number significantly at 5 days after treatment ([Figure 1](#cancers-10-00283-f001){ref-type="fig"}b). To determine whether the reduction in cell number is accompanied by reduced cell proliferation, we examined the effects of CX-4945 on 5-bromo-2′-deoxyuridine (BrdU) incorporation. CX-4945 at 25 and 50 µM inhibited BrdU incorporation on all CCA cell lines by approximately 50% and 25%, respectively, at 24 h post-treatment ([Figure 1](#cancers-10-00283-f001){ref-type="fig"}c). A slightly lower inhibition was observed on CCLP-1 cells ([Figure 1](#cancers-10-00283-f001){ref-type="fig"}c).

2.3. CX-4945 Treatment Alters Cell Invasion {#sec2dot3-cancers-10-00283}
-------------------------------------------

Protein kinase CK2 is known to be important in cell migration and cancer cell invasion. To determine the effects of CX-4945 on CCA cell invasion we examined the ability of the cells to traverse a layer of Matrigel in vitro. CX-4945 treatment showed biphasic effects on CCA cell invasion though Matrigel. CX-4945 at 10 µM significantly inhibited cell invasion through Matrigel in the three CCA cell lines tested ([Figure 1](#cancers-10-00283-f001){ref-type="fig"}d). In contrast, lower concentrations of CX-4945 stimulated invasion in all CCA cell lines tested ([Figure 1](#cancers-10-00283-f001){ref-type="fig"}d). The increase in cell invasion at low CX-4945 doses was not due to an increase in cell number as the assays were performed at the same time point (24 h post-treatment) that was shown by BrdU assay to have equivalent proliferation rates between the control and CX-4945 treated groups (1 and 5 µM) ([Figure 1](#cancers-10-00283-f001){ref-type="fig"}c). In addition, MTT assay at a later time point (48 h post-treatment) also showed no difference in cell number between these groups ([Figure 1](#cancers-10-00283-f001){ref-type="fig"}b). The increase in cell invasion was at least in part due to an increase in MMP-9, MMP-7, and matrix metallopeptidase 2 (MMP-2) levels in CCLP-1, and an increase in MMP-7 levels in HuCCA-1 and KKU-M213 ([Figure 1](#cancers-10-00283-f001){ref-type="fig"}e,f). The decrease in cell invasion at 10 µM of CX-4945 was at least in part due to a decrease in MMP-9 and MMP-7 levels in HuCCA-1 and to MMP-7 levels in KKU-M213. In addition to a decrease in MMP levels, a smaller invasion in the 10 µM CX-4945-treated group was also likely to be a consequence of the inhibition of cell proliferation at this dose ([Figure 1](#cancers-10-00283-f001){ref-type="fig"}b,c). We conclude that at lower doses, CX-4945 treatment increased the ability of CCA cells to invade Matrigel, while higher doses inhibited this ability.

2.4. CX-4945 Treatment Induces Intensive Vacuolization {#sec2dot4-cancers-10-00283}
------------------------------------------------------

Prominent vacuoles were observed as soon as 1 h after CX-4945 treatment in all CCA cell lines tested ([Figure 2](#cancers-10-00283-f002){ref-type="fig"}a--c). The number of the vacuoles at 24 h post-treatment increased in a dose-dependent manner in CX-4945 treated HuCCA-1, CCLP-1, and KKU-M213 cells ([Figure 2](#cancers-10-00283-f002){ref-type="fig"}d,h,l). The number of vacuoles also increased in a time-dependent manner until 4 h post-treatment in HuCCA-1 ([Figure 2](#cancers-10-00283-f002){ref-type="fig"}e) or 2 h after treatment in CCLP-1 and KKU-M213 ([Figure 2](#cancers-10-00283-f002){ref-type="fig"}i,m) before declining at later time points. This reduction in vacuole number might be due to the fusion of small vacuoles into larger ones. In keeping with this view, the size of the vacuoles increased in a dose- and time-dependent manner ([Figure 2](#cancers-10-00283-f002){ref-type="fig"}f,g,j,k,n,o). The vacuoles filled most of the cytoplasm at 24 h after treatment in cells treated with 50 µM CX-4945 ([Figure 2](#cancers-10-00283-f002){ref-type="fig"}a--c). To determine whether vacuole formation is limited to CCA cells, we next treated a variety of other CCA cells and non-CAA cells with CX-4945. CX-4945 treatment induced vacuole formation in all of the additional CCA cell lines tested ([Figure 3](#cancers-10-00283-f003){ref-type="fig"}a). Furthermore, 50 µM CX-4945 treatment at 4 h also induced intensive vacuolization in immortalized cholangiocytes (MMNK-1 and AKN-1 cells), as well as breast cancer cell lines (MDA-MB-231 and T47D), prostate cancer cell line DU145, and human embryonic kidney cells (HEK293T). However, one prostate cancer cell line (PC3) did not form vacuoles at all under the conditions tested, and one breast cancer cell line (MCF-7) formed only a few vacuoles in some cells ([Figure 3](#cancers-10-00283-f003){ref-type="fig"}a). Interestingly, although the cell area of the cell lines that form vacuoles did not decrease ([Figure 3](#cancers-10-00283-f003){ref-type="fig"}b), PC3 cell area decreased approximately 50% as compared to the vehicle control group ([Figure 3](#cancers-10-00283-f003){ref-type="fig"}b).

2.5. CX-4945 Induces Caspase-3 Independent Non-Autophagic Cell Death in CCA Cells {#sec2dot5-cancers-10-00283}
---------------------------------------------------------------------------------

To determine whether vacuolization was accompanied by increased cell death, we treated CCA cells with CX-4945 and stained live cells with calcein and dead cells with propidium iodide. No significant increase in the number of dead cells was observed after 4 h of CX-4945 treatment ([Figure 4](#cancers-10-00283-f004){ref-type="fig"}a,c,e), which was the time point where a decreased level of CK2 activity was observed with CX-4945 treatment ([Figure 1](#cancers-10-00283-f001){ref-type="fig"}a). However, CX-4945 at 25 and 50 µM significantly induced cell death in HuCCA-1 cells ([Figure 4](#cancers-10-00283-f004){ref-type="fig"}b) and KKU-M213 cells ([Figure 4](#cancers-10-00283-f004){ref-type="fig"}f) at 48 h post-treatment. Although there was no significant increase in the number of dead CCLP-1 cells following treatment with CX-4945, the total number of cells 48 h post-treatment was clearly reduced ([Figure 4](#cancers-10-00283-f004){ref-type="fig"}d, calcein panels). This was also seen in the other cell lines ([Figure 4](#cancers-10-00283-f004){ref-type="fig"}b,f). The percentage of dead cells was increased in a dose-dependent manner from approximately 1--3% in the vehicle control group to 12% (CCLP-1) or 20% (HuCCA-1 and KKU-M213) in 50 µM treated group ([Figure 4](#cancers-10-00283-f004){ref-type="fig"}g). Interestingly, the number of apoptotic cells did not increase in these cells after treatment with CX-4945 at any concentration for 48 h ([Figure 5](#cancers-10-00283-f005){ref-type="fig"}a), while cell death was detected at 48 h post-treatment. Etoposide treated KKU-M213 cells were used as positive control for the cleaved caspase-3 apoptosis assay. Furthermore, the vacuoles that presented after CX-4945 treatment do not appear to be autophagosomes since levels of the autophagosomal marker LC3B-II decreased ([Figure 5](#cancers-10-00283-f005){ref-type="fig"}a) while the number and size of the vacuoles increased ([Figure 2](#cancers-10-00283-f002){ref-type="fig"}). Although HuCCA-1 treated with 10 and 25 µM CX-4945 showed an increased level of LC3B-II, the cells treated with 50 µM, which is the concentration where the highest number of vacuoles was observed, showed a decreased level of LC3B-II. Moreover, a decreased level of LC3B-II was observed in both CCLP-1 and KKU-M213 treated with CX-4945 ([Figure 5](#cancers-10-00283-f005){ref-type="fig"}a). To further examine the involvement of LC3B-II in the vacuolization induced by CX-4945, a time-course treatment of 50 µM CX-4945 was performed. The level of LC3B-II was elevated at early time points post-treatment in HuCCA-1 and CCLP-1 cells, but it decreased significantly at 4 h post-treatment. A similar trend was observed in KKU-M213 cells where the level of LC3B-II at earlier time points was higher than that at 4 h ([Figure 5](#cancers-10-00283-f005){ref-type="fig"}b,c). We conclude that CX-4945 is likely to induce non-canonical cell death in these cell lines. However, the LC3B-II protein might be involved in the initiation of vacuole formation.

2.6. CX-4945 Induced Methuosis in KKU-M213 {#sec2dot6-cancers-10-00283}
------------------------------------------

All cell lines used in these studies, except PC3 cells which did not form vacuoles ([Figure 3](#cancers-10-00283-f003){ref-type="fig"}a), showed no change in cell area ([Figure 3](#cancers-10-00283-f003){ref-type="fig"}b) and had no membrane blebbing ([Figure 3](#cancers-10-00283-f003){ref-type="fig"}a). Although their cytoplasm was filled with vacuoles, the cell membrane was well-spread and cell shape was normal as compared to the vehicle control group ([Figure 3](#cancers-10-00283-f003){ref-type="fig"}a). To further identify the cell death mechanism induced by CX-4945 in CCA cell lines, the nucleus and ER of cells treated with CX-4945 were examined. First, nuclear staining with DAPI showed that the nucleus of cells treated with 25 µM CX-4945 for 24 h were still intact. No chromatin condensation or nuclear fragmentation was observed ([Figure 6](#cancers-10-00283-f006){ref-type="fig"}a). Second, KKU-M213, which are cells that are most sensitive to CX-4945 in terms of vacuole formation, were incubated for 72 h with CellLight^®^ ER-GFP BacMam 2.0 (C10590, Fisher Scientific, Hampton, NH, USA). This reagent transfected and expressed GFP-fused ER signal sequence, calreticulin, and KDEL, in live cells, thereby labeled ER with GFP. The ER of KKU-M213 treated with CX-4945 covered a large part of cytoplasm but did not overlap with the vacuoles ([Figure 6](#cancers-10-00283-f006){ref-type="fig"}b). Some large vacuoles reside near the nucleus and, therefore, share a similar space as the ER in the cytoplasm, however, many other medium and small vacuoles as well as some other large vacuoles were observed in the area not overlapping with the ER ([Figure 6](#cancers-10-00283-f006){ref-type="fig"}b). In addition, dextran blue/yellow was added in the culture media during CX-4945 treatment to track the endocytosis process. KKU-M213 engulfed dextran blue/yellow into the vacuoles, which showed as blue dots of various sizes in the cytoplasm ([Figure 6](#cancers-10-00283-f006){ref-type="fig"}c). Dextran blue/yellow remained blue indicating that pH of the vacuoles was neutral since it changes to green or yellow when the environment is acidic. We conclude that the vacuoles formed from CX-4945 treatment did not alter nuclear and membrane integrity. Furthermore, vacuoles in KKU-M213 are not formed from the ER, instead they are formed from the endocytosis process as their pH is neutral. These finding meet the criteria for methuosis.

2.7. CX-4945 Induced Vacuolization Is CK2-Independent {#sec2dot7-cancers-10-00283}
-----------------------------------------------------

To determine whether the effects of CX-4945 on vacuole formation were mediated by the inhibition of CK2, we next knocked down the expression of the α and α′ CK2 catalytic subunits using specific siRNAs ([Figure 7](#cancers-10-00283-f007){ref-type="fig"}a). Knockdown of both CK2 α and α′ in the HuCCA-1, CCLP-1, and KKU-M213 CCA cell lines was verified using Western blotting ([Figure 6](#cancers-10-00283-f006){ref-type="fig"}a). In all three cell lines, knockdown of CK2 α and CK2 α′ decreased the levels of multiple phospho-CK2 substrates ([Figure 7](#cancers-10-00283-f007){ref-type="fig"}b). A reduction in phospho-CK2 substrate levels was observed for proteins with apparent molecular masses of 180, 110, 60, and 37 kDa as indicated by arrows in the Figure ([Figure 7](#cancers-10-00283-f007){ref-type="fig"}b). However, CK2 α and CK2 α′ knockdown failed to induce vacuolization in any of the CCA cell lines ([Figure 7](#cancers-10-00283-f007){ref-type="fig"}c). To confirm these results, we next treated CCA cell lines with 4,5,6,7-Tetrabromobenzotriazole (TBB), a well-characterized inhibitor of CK2 activity. Treatment with TBB did not induce the formation of vacuoles in any of the three CCA cells lines ([Figure 7](#cancers-10-00283-f007){ref-type="fig"}e--g) although it did block the phosphorylation of multiple CK2 substrates in HuCCA-1 and KKU-M213 cell lines ([Figure 7](#cancers-10-00283-f007){ref-type="fig"}d). We conclude that the induction of vacuoles by CX-4945, at least in HuCCA-1 and KKU-M213 cells, is not mediated by the inhibition of CK2 activity.

2.8. CK2 Knockdown Inhibited CCA Cell Proliferation and Cell Invasion {#sec2dot8-cancers-10-00283}
---------------------------------------------------------------------

To investigate the effects of CK2 α and CK2 α′ knockdown on CCA cell proliferation, we next examined cell number and assayed BrdU incorporation. Combined CK2 α and CK2 α′ knockdown had no effect on HUCCA-1 cell number over 5 days in culture and only a modest effect on the number of CCLP-1 and KKU-M213 cells ([Figure 8](#cancers-10-00283-f008){ref-type="fig"}a). CCLP-1 and KKU-M213 cell number was decreased by 25% at 5 days after gene knockdown. In contrast to the biphasic effects of CX-4945 treatment on CCA cell invasion, combined CK2 α and CK2 α′ knockdown inhibited CCA cell invasion in HuCCA-1 and KKU-M213 cells. HuCCA-1 cell invasion was inhibited to approximately 60% of the control, while KKU-M213 cell invasion was inhibited to approximately 45% of the control ([Figure 8](#cancers-10-00283-f008){ref-type="fig"}b). Moreover, CK2 α and CK2 α′ knockdown had no effect on invasion of CCLP-1 cells. We conclude that the effects of CX-4945 treatment on CCA cell proliferation and cell invasion are unlikely to be mediated by the inhibition of CK2 in these cells.

3. Discussion {#sec3-cancers-10-00283}
=============

CX-4945 is in clinical phase I/II trials for cholangiocarcinoma ([ClinicalTrials.gov](ClinicalTrials.gov) identifier: NCT02128282). Moreover, this drug has shown a therapeutic potential in several other types of cancer \[[@B17-cancers-10-00283],[@B22-cancers-10-00283],[@B28-cancers-10-00283],[@B44-cancers-10-00283],[@B45-cancers-10-00283],[@B46-cancers-10-00283]\]. Herein, CX-4945, at 10 μM and above, was shown to decrease protein kinase CK2 activity when delivered to CCA cells and to inhibit CCA cell proliferation ([Figure 1](#cancers-10-00283-f001){ref-type="fig"}). Unexpectedly, treatment with CX-4945 had biphasic effects on the ability of CCA cells to invade Matrigel. At 10 µM, CX-4945 inhibited CCA cell invasion through a reduction of MMP-9 and MMP-7 levels plus an inhibitory effect on cell proliferation. Interestingly, lower doses of CX-4945 (1 and 5 µM) increased the levels of MMP-9, MMP-7, and MMP-2 ([Figure 1](#cancers-10-00283-f001){ref-type="fig"}e,f). A biphasic effect of CX-4945 on cell proliferation has been reported previously in s22Rv1 prostate cancer cells \[[@B25-cancers-10-00283]\], UM-SCC1 head and neck cancer cells \[[@B47-cancers-10-00283]\], and A549 lung cancer cells \[[@B48-cancers-10-00283]\]. CX-4945 at 0.5, 0.1, and 0.01 µM slightly stimulated cell proliferation in the aforementioned cell lines, whereas higher doses inhibited cell proliferation \[[@B25-cancers-10-00283],[@B47-cancers-10-00283],[@B48-cancers-10-00283]\]. Knockdown of the α and α′ catalytic subunits of CK2 simultaneously also significantly reduced the phosphorylation of multiple CK2 substrates indicating that CK2 knockdown and CX-4945 treatment both inhibited CK2 activity. We measured CK2 activity indirectly by using an antibody against the phospho-CK2 substrate (motif pS/pTDXE) to measure the amount of phosphorylated CK2 substrates. This method is widely used in literature to measure kinase activity, such as activity of the following kinases CK2 \[[@B16-cancers-10-00283],[@B49-cancers-10-00283],[@B50-cancers-10-00283],[@B51-cancers-10-00283],[@B52-cancers-10-00283]\], AMPK \[[@B53-cancers-10-00283],[@B54-cancers-10-00283],[@B55-cancers-10-00283],[@B56-cancers-10-00283],[@B57-cancers-10-00283],[@B58-cancers-10-00283],[@B59-cancers-10-00283],[@B60-cancers-10-00283],[@B61-cancers-10-00283],[@B62-cancers-10-00283],[@B63-cancers-10-00283]\], AMT/ATR \[[@B64-cancers-10-00283],[@B65-cancers-10-00283],[@B66-cancers-10-00283],[@B67-cancers-10-00283],[@B68-cancers-10-00283],[@B69-cancers-10-00283],[@B70-cancers-10-00283]\], PKA \[[@B71-cancers-10-00283],[@B72-cancers-10-00283],[@B73-cancers-10-00283],[@B74-cancers-10-00283],[@B75-cancers-10-00283],[@B76-cancers-10-00283],[@B77-cancers-10-00283],[@B78-cancers-10-00283],[@B79-cancers-10-00283]\], and PKC \[[@B77-cancers-10-00283],[@B80-cancers-10-00283],[@B81-cancers-10-00283],[@B82-cancers-10-00283],[@B83-cancers-10-00283],[@B84-cancers-10-00283],[@B85-cancers-10-00283],[@B86-cancers-10-00283],[@B87-cancers-10-00283],[@B88-cancers-10-00283]\]. Both CK2 knockdown and CX-4945 treatment inhibited the proliferation of CCA cells. However, in contrast to the biphasic effects of CX-4945 on CCA cell invasion, CK2 knockdown only inhibited CCA cell invasion. These data suggest that CX-4945 treatment increases CCA cell invasion independently of CK2 inhibition. In addition, intensive vacuolization and cell death was observed following CX-4945 treatment ([Figure 2](#cancers-10-00283-f002){ref-type="fig"} and [Figure 3](#cancers-10-00283-f003){ref-type="fig"}), but vacuolization was absent following CK2α and CK2α′ knockdown ([Figure 7](#cancers-10-00283-f007){ref-type="fig"}c) and following treatment with another CK2 inhibitor ([Figure 7](#cancers-10-00283-f007){ref-type="fig"}e--g). This suggests that the induction of vacuole formation is also an off target effect of CX-4945. Recently, an off target effect of CX-4945 was reported. CX-4945 was reported to inhibit the Cdc2-like kinases (Clks) resulting in a suppression of phosphorylation of serine/arginine (S/R) rich proteins in mammalian cells \[[@B31-cancers-10-00283]\]. In addition, CX-4945 has been shown to affect alternative splicing of a wide range of genes in a CK2-independent manner \[[@B31-cancers-10-00283]\]. Inhibition of these or other kinases may be responsible for increased cell invasion and/or increased vacuolization and cell death.

It has been reported that CX-4945 induces apoptosis via caspase-3 activity in lung cancer cells \[[@B17-cancers-10-00283]\] and in primary CCA tumor lines \[[@B28-cancers-10-00283]\]. Autophagy was induced by CX-4945 in pancreatic and lung cancer cell lines \[[@B45-cancers-10-00283],[@B89-cancers-10-00283]\]. Surprisingly, we have shown that CX-4945-induced cell death in CCA cell lines was not accompanied by caspase-3 cleavage and did not appear to involve autophagy ([Figure 5](#cancers-10-00283-f005){ref-type="fig"}a,b) despite the involvement of intensive cytoplasmic vacuolization. This phenomenon was observed in a range of cell lines including CCA cell lines, immortalized cholangiocyte cell lines, breast and prostate cancer cell lines, and HEK293T cells. CX-4945-induced vacuoles originated from an engulfment of extracellular fluid, not from the ER. ([Figure 6](#cancers-10-00283-f006){ref-type="fig"}b,c). Interestingly, non-canonical cell death involving intensive cytoplasmic vacuolization is a hallmark of methuosis, oncosis, paratosis, and necroptosis \[[@B35-cancers-10-00283]\]. We propose that the non-apoptotic, non-autophagic cell death mechanism induced by CX-4945 is not oncosis, paraptosis, or necroptosis according to the following criteria. First, no membrane blebbing was observed ([Figure 3](#cancers-10-00283-f003){ref-type="fig"}a). Second, chromatin condensation and nuclear fragmentation were absent ([Figure 6](#cancers-10-00283-f006){ref-type="fig"}a). Third, the vacuoles originated from an engulfment of extracellular fluid, not from the ER ([Figure 6](#cancers-10-00283-f006){ref-type="fig"}b,c) \[[@B35-cancers-10-00283]\]. Furthermore, the vacuoles merged with others into large vacuoles ([Figure 2](#cancers-10-00283-f002){ref-type="fig"}) and their pH remained neutral ([Figure 6](#cancers-10-00283-f006){ref-type="fig"}c). All of the aforementioned data fit the criteria of methuosis, therefore, we propose that CX-4945 induces methuosis at least in the CCA cell line KKU-M213.

Interestingly, PC3 prostate cancer cells did not form vacuoles. This absence of the vacuoles in PC3 cells suggests a cell line specific response to CX-4945. It seems likely that CX-4945 activity and its effects on cell death are cell-type specific, that is, dependent on, for example, whether tumor suppressors such as TP53 are wild type or mutant in the cell line being tested. Further study on the PC3 cell line might elucidate the molecular mechanism underlying the CX-4945-induced vacuolization and cell death reported in this study. Further investigation of the molecular mechanisms underlying CX-4945-induced vacuolization and cell death might lead to a better understanding of possible combinations of this treatment with other current chemotherapeutic drugs to optimize treatment outcomes in patients.

4. Materials and Methods {#sec4-cancers-10-00283}
========================

4.1. Cell Culture {#sec4dot1-cancers-10-00283}
-----------------

Two cholangiocarcinoma cell lines, KKU-M055 and KKU-M213, established as previously described \[[@B90-cancers-10-00283]\], were purchased from the Japanese Collection of Research Bioresources (JCRB) Cell Bank (Osaka, Japan). These two cell lines were from a Thai patient with an *Opisthorchis viverrini* record. The immortalized cholangiocytes cell line, MMNK-1, was also purchased from the JCRB Cell Bank. Intraheptic cholangiocarcinoma cell lines, HuCCA-1 were established and kindly provided by Prof. Stitaya Sirisinha \[[@B91-cancers-10-00283]\]. HuCCA-1 was derived from a Thai patient whose serum was positive for the *O. viverrini* antigen \[[@B91-cancers-10-00283]\]. Prostate cancer cell lines, PC3 and DU145, were purchased from American Type Culture Collection (ATCC) (Manassas, VA, USA). The immortalized human cholangiocytes cell line, AKN-1, and cholangiocarcinoma cell lines, CCLP-1, were kindly provided by Dr. Simon Afford. Breast cancer cell lines, MDA-MB-231, T47D, MCF7, and HEK293T, were purchased from ATCC (Manassas, VA, USA). HuCCA-1 and PC3 cells were maintained in HAM's F-12 medium (Hyclone, Pittsburgh, PA, USA) supplemented with 10% fetal bovine serum (FBS) (Gibco, Grand Island, NY, USA), while CCLP-1, KKU-M055, KKU-M213, MMNK-1, AKN-1, DU145, HEK293T, MDA-MB-231, T47D, and MCF7 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) (Hyclone, Pittsburgh, PA, USA) supplemented with 10% FBS and 1% MEM non-essential amino acid (Gibco, Grand Island, NY, USA). All media were supplemented with 1% Penicillin/Streptomycin (Gibco, Grand Island, NY, USA). All cell lines were maintained at 37 °C with 5% CO~2~.

4.2. MTT Assay {#sec4dot2-cancers-10-00283}
--------------

Cells were plated in tissue culture treated 96-well plates. After overnight adhesion to the plate, the treatment group was incubated with the indicated concentrations of CX-4945 (Santa Cruz Biotechnology, Dallas, TX, USA) or 4,5,6,7-tetrabromo-2-azabenzimidazole, 4,5,6,7-Tetrabromobenzotriazole (TBB) (Sigma Aldrich, St. Louis, MO, USA). Media were changed and new treatments were added on day 2. On day 0, 2, and 5, MTT reagent (Fisher Scientific, Hampton, NH, USA) was added to the final concentration of 0.5 mg/mL and incubated for 2.5 h at 37 °C. A half volume of stop solution (10% Sodium dodecyl sulfate (SDS) in 50% dimethylformamide in dH~2~O) was added and mixed thoroughly before reading the absorbance at 560 nm on a plate reader.

4.3. BrdU Incorporation Assay {#sec4dot3-cancers-10-00283}
-----------------------------

Cells were plated in tissue culture treated 96-well plates. BrdU incorporation was assessed by using a BrdU Cell Proliferation kit (ab126556, Abcam, Cambridge, MA, USA). Cells were treated with CX-4945 for 24 h. During the last 6 h, cells were incubated in a working stock of BrdU. After incubation with BrdU, media was removed and a fixative was added and the plates were incubated for 30 min at 23 °C. Reaction cocktail was added according to the manufacturer's protocol. The plate was read with a spectrophotometer plate reader at an absorbance at 450 nm. The average no BrdU background measurement was subtracted from all experimental measurements.

4.4. Cell Invasion Assay {#sec4dot4-cancers-10-00283}
------------------------

Eight micrometer polycarbonate membrane transwell inserts (Corning costar, New York, NY, USA) were coated with 50 µL of a 1:9 ratio of Matrigel™ (BD Biosciences, San Jose, CA, USA) to serum free medium, that was allowed to congeal at 37 °C for 30 min. A total of 5 × 10^4^ cells was added to the top chamber of each well in serum free medium. The bottom well was filled with complete medium. Treatment was added in both the transwell and the bottom well. Cells were incubated for 24 h at a 37 °C in a humidified incubator with 5% CO~2~. The chambers were swabbed to remove cells and the Matrigel™ remaining on the top of the membrane. Cells on the underside of the membrane were fixed in methanol for 5 min and stained with 0.5% (*w*/*v*) crystal violet in 12% glutaraldehyde in water for 5 min. Following a brief distilled H~2~O wash, cells were counted using a Nikon Eclipse T2S phase contrast inverted fluorescent microscope.

4.5. Cell Viability Assay {#sec4dot5-cancers-10-00283}
-------------------------

Cells were plated in tissue culture treated 6-well plates and incubated overnight. CX-4945 treatments were added and incubated for either 4 h or 48 h. Calcein-acetoxymethyl (AM) (Fisher Scientific) and propidium iodide (Fisher Scientific) were added 30 min before imaging at a final concentration of 0.125 µM and 1.5 µM, respectively. Images were taken with Nikon Eclipse T2S phase contrast inverted fluorescent microscope. Live cells were stained with calcein and showed a green fluorescent signal while dead cells were stained with Propidium iodine and showed a red fluorescent signal. Green and red fluorescence pixels were counted using Adobe Photoshop software. Average live and dead cells sizes were measured using Adobe Photoshop software.

4.6. Western Blot Analysis {#sec4dot6-cancers-10-00283}
--------------------------

A total of 20 µg of protein was separated electrophoretically and transferred to nitrocellulose membrane (GE, Boston, MA, USA) at room temperature. Membranes were blocked in a blocking buffer (4% bovine serum albumin (BSA) *w*/*v* in Tris-buffered saline, 0.1% Tween 20 (TBST)), and then incubated with primary antibodies overnight at 4 °C on a rocking shaker. All antibodies were diluted in blocking buffer. All primary antibodies were monoclonal rabbit anti-human antibodies. Primary antibodies included 1:1500 MMP-9 (2270, Cell Signaling Technology, Danvers, MA, USA), 1:1000 MMP-7 (ab5706, Abcam), 1:1500 MMP-2 (4022, Cell Signaling Technology), 1:1500 cleaved caspase-3 (9664, Cell Signaling Technology), 1:1500 phospho-CK2 substrate (motif pS/pTDXE) (8738, Cell Signaling Technology), 1:1500 LC3B (3868, Cell Signaling Technology), and 1:5000 β-actin (A2066, Sigma Aldrich, St. Louis, MO, USA). Membranes were incubated for 75 min on a rocking shaker at 23 °C with secondary antibodies. Secondary antibodies included 1:5000 goat anti-rabbit IgG conjugated with horseradish peroxidase (7074, Cell Signaling Technology) or 1:5000 horse anti-mouse immunoglobulin G (IgG) conjugated with horseradish peroxidase (7076, Cell Signaling Technology). Signal was visualized by autoradiography using enhanced chemiluminescence (ECL) and a horseradish peroxidase (HRP) chemiluminescent substrate (Millipore, Burlington, MA, USA), and exposed to Hyperfilm (GE Healthcare, Boston, MA, USA). Bands intensity was analyzed using ImageJ software.

4.7. siRNA Transfection {#sec4dot7-cancers-10-00283}
-----------------------

Transfection was performed by adding 4 × 10^5^ cells to 100 nM siRNA mixture in Optimem medium (Fisher Scientific) in a total volume of 500 µL. siRNAs were commercially available from Qaigen (CK2α SI02660504 and SI02660497, CK2α′ SI00605416 and SI00605409). The mixture of siRNA and cells was plated into 6-well plates and incubated in a 37 °C humidified incubator with 5% CO~2~ for 4 h. Complete growth medium was then added and incubated for 2 days before cells were used in further experiments.

4.8. Organelle Labeling and Imaging {#sec4dot8-cancers-10-00283}
-----------------------------------

Cells were plated in tissue culture treated 6-well plates and incubated overnight. CellLight™ ER-GFP and BacMam 2.0 (C10590, Fisher Scientific) were added to cells and incubated for 72 h at 50 particles per cell. LysoSensor™ Yellow/Blue DND-160 (L7545 Fisher Scientific) was added 15 min before the treatment. Treatment (25 µM CX-4945) was added and incubated for 6 h. Fresh culture media was changed prior to imaging. Live cells were imaged with a fluorescent invested microscope with cell culture chamber module (Olympus) at the Olympus Imaging Center, Mahidol University. Cells were plated on circle cover slides in tissue culture 24-well plates and incubated overnight. Twenty-five micromolars of CX-4945 was added and incubated for 24 h. Cells were fixed in 3.7% formaldehyde in Phosphate buffered saline (PBS) for 10 min, and then permeabilized in 0.1% Triton X-100 in PBS for 2 min. After incubation, cells were incubated in 300 nM DAPI in PBS to stain the nuclei. Fixed cells were imaged with a confocal microscope (Olympus) at the Olympus Imaging Center, Mahidol University.

4.9. Statistical Analysis {#sec4dot9-cancers-10-00283}
-------------------------

Data were graphed as mean ± standard error of the mean (SEM) using Prism Graphpad software (version 6.01, GraphPad Software, La Jolla, CA, USA). Statistical analyses were performed using ANOVA with Dunnett's test by using JMP software (version 10.0.0, SAS Institute Inc., Cary, NC, USA). All experiments were performed in triplicate.

5. Conclusions {#sec5-cancers-10-00283}
==============

Our data suggest that CX-4945 inhibits cell proliferation and induces methuosis via CK2-independent pathways. A biphasic effect of CX-4945 on CCA cell invasion was, at least in part, due to an alteration of MMP-2, MMP-7, and MMP-9.
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![The effects of CX-4945 on cholangiocarcinoma (CCA) cell lines. (**a**) CX-4945 (Silmitasertib) inhibited CK2 (previously casein kinase II) activity in a dose-dependent manner. Arrows indicate CK2 phospho-substrates that decrease in intensity with CX-4945 treatment. (**b**) CX-4945 at 5 µM and higher doses reduced CCA cell number in three CCA cell lines as determined using MTT assays. (**c**) CX-4945 at 25 and 50 µM inhibited CCA cell lines proliferation in a 5-bromo-2′-deoxyuridine (BrdU) incorporation assay 24 h post-treatment. (**d**) CX-4945 exerted a biphasic effect on cell invasion through Matrigel. CX-4945 at 5 µM or lower doses induced invasion by HuCCA-1 cells and KKU-M213 cells while CX-4945 at 10 µM inhibited CCA cell invasion through Matrigel. (**e**) Twenty-four hours' post-treatment of CX-4945 at low doses upregulated matrix metallopeptidase 7 (MMP-7) level while 10 µM CX-4945 downregulated MMP-7 level. MMP-2 and MMP-9 levels were not altered. (**f**) Quantitative data of protein level changes post treatment of CX-4945 in panel (**e**). VC; vehicle control, \*; *p* \< 0.05, \*\*; *p* \< 0.01, \*\*\*; *p* \< 0.001. All experiments were performed in triplicate and with at least at three biological replicates. Graphs were plotted as mean ± SEM.](cancers-10-00283-g001){#cancers-10-00283-f001}

![CX-4945 induced vacuolization. (**a**--**c**) CX-4945 induced intensive vacuolization in CCA cells. CX-4945 induced vacuolization in CCA cell lines in a dose- (**d**,**f**,**h**,**j**,**l**,**n**) and time- (**e**,**g**,**i**,**k**,**m**,**o**) dependent manner. VC; vehicle control, \*; *p* \< 0.05, \*\*; *p* \< 0.01, \*\*\*; *p* \< 0.001, \#; significantly different from all other groups at *p* \< 0.001. All experiments were performed with at least three biological replicates. Graphs were plotted as mean ± SEM.](cancers-10-00283-g002){#cancers-10-00283-f002}

![CX-4945 induced vacuolization in a wide range of cancer and immortalized cell lines. (**a**) CCA cells (HuCCA-1, CCLP-1, KKU-M213, KKU-M055, and KKU-100) and immortalized cholangiocytes (MMNK-1 and AKN-1), breast cancer cells (MDA-MB-231 and T48D), prostate cancer cells (DU145), and human embryonic kidney cells (HEK293T) form intensive cytoplasmic vacuoles at 4 h after CX-4945 treatment. Breast cancer cells, MCF-7, formed only few vacuoles in small number of cells, while prostate cancer cell, PC3, did not form any vacuoles. (**b**) Cell area of cell lines that formed vacuoles did not altered, but PC3 cell area decreased to approximately 50% as compared to the vehicle control group. VC; vehicle control, \*\*\*; *p* \< 0.001, NS; not significant. Pictures are representative of the results from three independent experiments. Graphs were plotted as mean ± SEM.](cancers-10-00283-g003){#cancers-10-00283-f003}

![CX-4945 induced cell death. Propidium iodide staining showed that treatment with CX-4945 for 4 h did not induce cell death in (**a**) HuCCA-1, (**c**) CCLP-1, and (**e**) KKU-M213 cells. Extended CX-4945 treatment at 48 h, however, induced extensive cell death in (**b**) HuCCA-1 and (**f**) KKU-M213 cell lines. (**d**) Dead cell number was not increased in CCLP-1 treated with CX-4945 but live cell number clearly decreased in the 25 and 50 µM CX-4945 treated samples as well as in (**b**) HuCCA-1 and (**f**) KKU-M213 cell lines. (**g**) Percentage of dead cell increased in a dose-dependent manner in all three CCA cell lines. \*\*\*; *p* \< 0.001, Pictures are representative of the results from three independent experiments.](cancers-10-00283-g004){#cancers-10-00283-f004}

![CX-4945 induced non-apoptotic, non-autophagic cell death. (**a**) The apoptotic marker, cleaved caspase-3, and autophagic marker, LC3B-II, was not increased after 48 h of CX-4945 treatment when dead cells and vacuoles were observed. (**b**,**c**) The level of LC3B-II in HuCCA-1 and CCLP-1 cells increased at early time points, and then decreased after 3 h of 50 µM CX-4945 treatment in HuCCA-1 cells and after 4 h in CCLP-1 cells. The level of LC3B-II in KKU-M213 decreased as soon as 15 min after 50 µM CX-4945 treatment. VC; vehicle control, \*; *p* \< 0.05, \*\*; *p* \< 0.01, \*\*\*; *p* \< 0.001. All experiments were performed with at least three replicates. Graphs were plotted as mean ± SEM.](cancers-10-00283-g005){#cancers-10-00283-f005}

![CX-4945 induced methuosis in CCA cell line, KKU-M213. (**a**) CX-4945 induced cytoplasmic vacuolization in three CCA cell lines (HuCCA-1, CCLP-1, and KKU-M213) prostate cancer cell line (DU145), and breast cancer cell line (MDA-MB-231), while it left the nucleus intact as compared to the vehicle control group. (**b**) The endoplasmic reticulum (ER) of KKU-M213 showed no sign of swelling during vacuolization induced by CX-4945. (**c**) The vacuoles induced by CX-4945 contained dextran blue/yellow, which was added in the culture media during CX-4945 incubation. The presence of dextran blue/yellow in the vacuoles indicated that cell engulfed extracellular fluid and formed vacuoles. VC; vehicle control, arrow head indicates cytoplasmic vacuole.](cancers-10-00283-g006){#cancers-10-00283-f006}

![CK2 knockdown and inhibition of CK2 with 4,5,6,7-Tetrabromobenzotriazole (TBB) failed to induce vacuolization. (**a**) Knockdown of α and α′ catalytic subunits of protein kinase CK2 using small interfering (siRNA). (**b**) Knockdown of α and α′ catalytic subunits of protein kinase CK2 decreased phospho-CK2 substrate levels in HuCCA-1, CCLP-1, and KKU-M213 cell lines. (**c**) Knockdown of α and α′ catalytic subunits of protein kinase CK2 failed to induce cytoplasmic vacuolization. (**d**) TBB reduced levels of phospho-CK2 substrate levels in HuCCA-1 and KKU-M213 cell lines. (**e**--**g**) TBB failed to induce cytoplasmic vacuolization. WT; wild type, Scr; scramble siRNA. Pictures are representative of the results from three independent experiments.](cancers-10-00283-g007){#cancers-10-00283-f007}

![CK2 knockdown had little effect on CCA cell proliferation but inhibited cell invasion. (**a**) Knockdown of α and α′ catalytic subunits of protein kinase CK2 ([Figure 7](#cancers-10-00283-f007){ref-type="fig"}a) decreased CCLP-1 and KKU-M213 cell number as determined using MTT assays. (**b**) Knockdown of α and α′ catalytic subunits of protein kinase CK2 reduced HuCCA-1 and KKU-M213 cell invasion. WT; wild type, Scr; scramble siRNA, \*; *p* \< 0.05, \*\*; *p* \< 0.01, \*\*\*; *p* \< 0.001. All experiments were performed as at least three biological replicates. Graphs were plotted as mean ± SEM.](cancers-10-00283-g008){#cancers-10-00283-f008}

[^1]: Joint senior authors.
